Xvivo Perfusion ABXVIPF -1.32%87 Net-Net Working Capital is $0.90 as of Mar. 2026. GuruFocus rates XVIPF with a GF Score™ of 87/100 and a GF Value™ of $47.23 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 421 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 87.89% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Xvivo Perfusion AB's Net-Net Working Capital for the quarter that ended in Mar. 2026 was $0.90.
The industry rank for Xvivo Perfusion AB's Net-Net Working Capital or its related term are showing as below:
XVIPF's Price-to-Net-Net-Working-Capital is ranked worse than 87.89% of 421
companies
in the Medical Devices & Instruments industry
Industry Median: 6.84
vs XVIPF: 30.85
Xvivo Perfusion AB (OTCPK:XVIPF) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Xvivo Perfusion AB Net-Net Working Capital Related Terms
Xvivo Perfusion AB Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XVIPF vs ABT, SYK, MDT: Net-Net Working Capital Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Price-to-Net-Net-Working-Capital vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $0.90 mean?
Xvivo Perfusion AB (XVIPF) has a Net-Net Working Capital of $0.90 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Xvivo Perfusion AB According to the industry distribution chart, Xvivo Perfusion AB ranks #370 out of 421 companies in the Medical Devices & Instruments industry, placing it in the top 87.9%.
Is Xvivo Perfusion AB's Net-Net Working Capital too high?
Xvivo Perfusion AB's current Net-Net Working Capital is $0.90. The Medical Devices & Instruments industry median Net-Net Working Capital is 6.84. Xvivo Perfusion AB's value of $0.90 is 86.8% below this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #370 out of 421 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Net-Net Working Capital compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #370 out of 421 companies for Net-Net Working Capital. This places Xvivo Perfusion AB in the lower half of its industry. The industry median Net-Net Working Capital is 6.84. Xvivo Perfusion AB's value of $0.90 is 86.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Medical Devices & Instruments company?
The median Net-Net Working Capital among Medical Devices & Instruments companies is 6.84, based on 421 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Net-Net Working Capital of $0.90 is 86.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Xvivo Perfusion AB For the Medical Devices & Instruments industry, the median Net-Net Working Capital is 6.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Net-Net Working Capital is $0.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $47.23, compared to a current price of $29.00 — trading 38.6% below its estimated fair value. The current Net-Net Working Capital is $0.90 and 86.8% below the Medical Devices & Instruments industry median of 6.84. Xvivo Perfusion AB's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Net-Net Working Capital is $0.90 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 38.6% below its estimated GF Value™ of $47.23.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Net-Net Working Capital: $0.90
GF Value™: $47.23 vs. price of $29.00 (38.6% below fair value)
Industry Position: 86.8% below the Medical Devices & Instruments median (#370 of 421)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
87GF Score
Get the complete analysis for XVIPF
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
